4-(2-aminophenyl)benzylamine | 632339-00-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-aminophenyl)benzylamine
• 英文别名: 2-amino-4'-aminomethylbiphenyl；2-[4-(Aminomethyl)phenyl]aniline
• CAS: 632339-00-5
• 化学式: C₁₃H₁₄N₂
• 分子量: 198.268
• InChiKey: IDGDXDJLBXSMLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• METHOD FOR PRODUCING BIARYL COMPOUND
  申请人：Sato Koichi

  公开号：US20100087680A1

  公开（公告）日：2010-04-08

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种制备双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱的存在下，将芳香有机化合物与选自芳香基有机硼化合物和硼氧化物化合物组的至少一种化合物反应。
• PROCESS FOR PRODUCING BIARYL COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1914221A1

  公开（公告）日：2008-04-23

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种生产双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱存在下，使芳香族有机化合物与至少一种选自由芳香族有机硼化合物和硼氧化合物组成的组中的化合物反应。
• [EN] 1,2 DIAMIDO CYCLOALKYL SODIUM CHANNEL BLOCKERS<br/>[FR] COMPOSES 1,2 DIAMIDO CYCLOALKYLE BLOQUEURS DES CANAUX SODIQUES
  申请人：MERCK & CO INC

  公开号：WO2003101381A2

  公开（公告）日：2003-12-11

  1,2 Diamido cycloalkyl compounds that are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidin-dione and aryl-link-aryl oxazolodine-dione compounds and a pharmaceutically acceptable carrier; and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as irritable bowel syndrome, Crohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar disease, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolodine-dione compounds, either alone, or in combination with one or more therapeutically active compounds, are described.
• [EN] CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS<br/>[FR] COMPOSÉS CYCLOPROPYL-AMIDES UTILISÉS COMME INHIBITEURS DOUBLES DE LSD1/HDAC
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2017195216A1

  公开（公告）日：2017-11-16

  The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.
• [EN] COMBINATION OF A HDAC INHIBITOR AND VX MOLECULES, AND ITS USE FOR THE TREATMENT OF CYSTIC FIBROSIS<br/>[FR] COMBINAISON D'UN INHIBITEUR DE HDAC ET DE MOLÉCULES VX, ET SON UTILISATION POUR LE TRAITEMENT DE LA FIBROSE KYSTIQUE
  申请人：CENTRE DETUDE DES CELLULES SOUCHES CECS

  公开号：WO2021130381A1

  公开（公告）日：2021-07-01

  The present invention relates to the combination of a histone deacetylase (HDAC) inhibitor and a cystic fibrosis transmembrane conductance regulator (CFTR) modulator for use in the treatment of CFTR mediated diseases such as cystic fibrosis (CF).